Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Sunder-Plassmann

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Osteoarthritis and Cartilage|May 7, 2008
Cartilage biomarkers in hemodialysis patients and the effect of beta2-microglobulin on articular chondrocytesI-G Sunk, D Demetriou, J Szendroedi, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltrationF Thalhammer, P Schenk, H Burgmann, et al.
The International Journal of Artificial Organs|August 21, 2001
A controlled study of sorbent suspension dialysis in chronic liver disease and hepatic encephalopathyL Kramer, A Gendo, C Madl, et al.
Lancet (London, England)|December 5, 2009
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry dataA Mehta, M Beck, P Elliott, et al.
Anesthesia and Analgesia|March 29, 2000
Safe and efficient emergency transvenous ventricular pacing via the right supraclavicular routeK Laczika, F Thalhammer, G Locker, et al.
European Journal of Clinical Investigation|March 18, 2004
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome SurveyA Mehta, R Ricci, U Widmer, et al.
Kidney International|June 2, 1998
Major determinants of hyperhomocysteinemia in peritoneal dialysis patientsA Vychytil, M Födinger, G Wölfl, et al.
European Journal of Clinical Investigation|December 21, 2004
Fabry disease: overall effects of agalsidase alfa treatmentM Beck, R Ricci, U Widmer, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 29, 2001
Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patientsA C Hauser, W Hagen, P H Rehak, et al.
Clinical Pharmacology and Therapeutics|December 28, 2016
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics ConsortiumC H van der Wouden, A Cambon-Thomsen, E Cecchin, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Osteoarthritis and Cartilage|May 7, 2008
Cartilage biomarkers in hemodialysis patients and the effect of beta2-microglobulin on articular chondrocytesI-G Sunk, D Demetriou, J Szendroedi, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltrationF Thalhammer, P Schenk, H Burgmann, et al.
The International Journal of Artificial Organs|August 21, 2001
A controlled study of sorbent suspension dialysis in chronic liver disease and hepatic encephalopathyL Kramer, A Gendo, C Madl, et al.
Lancet (London, England)|December 5, 2009
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry dataA Mehta, M Beck, P Elliott, et al.
Anesthesia and Analgesia|March 29, 2000
Safe and efficient emergency transvenous ventricular pacing via the right supraclavicular routeK Laczika, F Thalhammer, G Locker, et al.
European Journal of Clinical Investigation|March 18, 2004
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome SurveyA Mehta, R Ricci, U Widmer, et al.
Kidney International|June 2, 1998
Major determinants of hyperhomocysteinemia in peritoneal dialysis patientsA Vychytil, M Födinger, G Wölfl, et al.
European Journal of Clinical Investigation|December 21, 2004
Fabry disease: overall effects of agalsidase alfa treatmentM Beck, R Ricci, U Widmer, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 29, 2001
Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patientsA C Hauser, W Hagen, P H Rehak, et al.
Clinical Pharmacology and Therapeutics|December 28, 2016
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics ConsortiumC H van der Wouden, A Cambon-Thomsen, E Cecchin, et al.
Pageof 10